Srikripa Devarakonda
Stock Analyst at Truist Securities
(4.21)
# 436
Out of 5,113 analysts
82
Total ratings
56%
Success rate
14.52%
Average return
Main Sectors:
Stocks Rated by Srikripa Devarakonda
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| BIIB Biogen | Maintains: Hold | $142 → $190 | $171.59 | +10.73% | 5 | Jan 8, 2026 | |
| PTGX Protagonist Therapeutics | Maintains: Buy | $88 → $110 | $83.10 | +32.37% | 4 | Jan 5, 2026 | |
| SEPN Septerna | Initiates: Buy | $34 | $25.80 | +31.78% | 1 | Dec 15, 2025 | |
| KYMR Kymera Therapeutics | Maintains: Buy | $80 → $116 | $69.93 | +65.88% | 6 | Dec 9, 2025 | |
| TERN Terns Pharmaceuticals | Maintains: Buy | $35 → $56 | $34.33 | +63.12% | 4 | Dec 9, 2025 | |
| MDGL Madrigal Pharmaceuticals | Maintains: Buy | $580 → $640 | $480.45 | +33.21% | 2 | Nov 19, 2025 | |
| INCY Incyte | Reiterates: Hold | $79 → $93 | $101.99 | -8.81% | 12 | Oct 29, 2025 | |
| SRRK Scholar Rock Holding | Maintains: Buy | $54 → $44 | $44.29 | -0.65% | 5 | Oct 20, 2025 | |
| VTRS Viatris | Initiates: Buy | $15 | $13.21 | +13.55% | 1 | Oct 15, 2025 | |
| MBX MBX Biosciences | Initiates: Buy | $50 | $37.85 | +32.10% | 1 | Oct 15, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $940 → $812 | $753.55 | +7.76% | 8 | Aug 11, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | $21 → $11 | $12.89 | -14.66% | 1 | May 5, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $43 → $25 | $19.19 | +30.28% | 5 | Apr 9, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $1,029 → $1,038 | $1,064.29 | -2.47% | 4 | Feb 3, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $211 → $217 | $219.26 | -1.03% | 3 | Feb 3, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $36 → $32 | $25.65 | +24.76% | 1 | Dec 18, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $33 → $50 | $28.61 | +74.76% | 6 | Nov 27, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $54 | $1.34 | +3,929.85% | 1 | Sep 27, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $18 → $15 | $6.38 | +135.11% | 7 | Aug 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $36 | $18.56 | +93.97% | 1 | Jul 31, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $86 → $70 | $63.41 | +10.39% | 4 | May 29, 2024 |
Biogen
Jan 8, 2026
Maintains: Hold
Price Target: $142 → $190
Current: $171.59
Upside: +10.73%
Protagonist Therapeutics
Jan 5, 2026
Maintains: Buy
Price Target: $88 → $110
Current: $83.10
Upside: +32.37%
Septerna
Dec 15, 2025
Initiates: Buy
Price Target: $34
Current: $25.80
Upside: +31.78%
Kymera Therapeutics
Dec 9, 2025
Maintains: Buy
Price Target: $80 → $116
Current: $69.93
Upside: +65.88%
Terns Pharmaceuticals
Dec 9, 2025
Maintains: Buy
Price Target: $35 → $56
Current: $34.33
Upside: +63.12%
Madrigal Pharmaceuticals
Nov 19, 2025
Maintains: Buy
Price Target: $580 → $640
Current: $480.45
Upside: +33.21%
Incyte
Oct 29, 2025
Reiterates: Hold
Price Target: $79 → $93
Current: $101.99
Upside: -8.81%
Scholar Rock Holding
Oct 20, 2025
Maintains: Buy
Price Target: $54 → $44
Current: $44.29
Upside: -0.65%
Viatris
Oct 15, 2025
Initiates: Buy
Price Target: $15
Current: $13.21
Upside: +13.55%
MBX Biosciences
Oct 15, 2025
Initiates: Buy
Price Target: $50
Current: $37.85
Upside: +32.10%
Aug 11, 2025
Maintains: Buy
Price Target: $940 → $812
Current: $753.55
Upside: +7.76%
May 5, 2025
Downgrades: Hold
Price Target: $21 → $11
Current: $12.89
Upside: -14.66%
Apr 9, 2025
Maintains: Buy
Price Target: $43 → $25
Current: $19.19
Upside: +30.28%
Feb 3, 2025
Maintains: Buy
Price Target: $1,029 → $1,038
Current: $1,064.29
Upside: -2.47%
Feb 3, 2025
Maintains: Buy
Price Target: $211 → $217
Current: $219.26
Upside: -1.03%
Dec 18, 2024
Maintains: Buy
Price Target: $36 → $32
Current: $25.65
Upside: +24.76%
Nov 27, 2024
Maintains: Buy
Price Target: $33 → $50
Current: $28.61
Upside: +74.76%
Sep 27, 2024
Upgrades: Buy
Price Target: $54
Current: $1.34
Upside: +3,929.85%
Aug 13, 2024
Maintains: Buy
Price Target: $18 → $15
Current: $6.38
Upside: +135.11%
Jul 31, 2024
Initiates: Buy
Price Target: $36
Current: $18.56
Upside: +93.97%
May 29, 2024
Maintains: Buy
Price Target: $86 → $70
Current: $63.41
Upside: +10.39%